ZNF618

Across TCGA pan-cancer cohorts, ZNF618 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF618 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZNF618 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF618 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where ZNF618 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.738	0.388	.001	35	view →
GBM	OS	Median	All	0.418	0.644	.008	5	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
LSCC	OS	Quartile	All	0.771	1.000	.026	2	view →
LUAD	OS	Quartile	All	1.000	0.730	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF618–CCRCC (DFS)

Open the CCRCC breakdown →